TAKHZYRO Now FDA-Approved for Children Aged 2-12 with HAE
In the past, there have been limited therapeutic options for pediatric patients living with hereditary angioedema (HAE). Children aged 2 to <6 years old had no approved prophylaxis therapy. For…